Gabapentin Tablet
Product Images NDC 76420-235

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76420-235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-600mg (Gabapentin 600mg)

The image shows multiple shipping labels for Gabapentin Tablets, USP 600 mg, packaged by Enovachem Pharmaceuticals. Each label displays different NDC package codes (76420-235-30, 76420-235-60, 76420-235-90, 76420-235-24, 76420-235-12) corresponding to package quantities of 30, 60, 90, 240, and 120 tablets respectively. The labels include manufacturer information (ScieGen Pharmaceuticals, Inc.), barcodes, QR codes, and standard cautionary text regarding prescription use and storage conditions.*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period and 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin scores declining more than placebo over time.*

FDA Label Image

Figure 2 (Image 02)

Line graph depicting mean pain scores over a 7-week period for placebo and two Gabapentin oral dose groups (1800 mg/day and 2400 mg/day). The horizontal axis represents weeks including a 3-week dose titration followed by a 4-week fixed dose period. The vertical axis shows mean pain score ranging from 0 to 10.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled "Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies" comparing placebo (PBO) and gabapentin (GBP) doses across two studies. It shows higher response proportions for gabapentin groups (GBP 3600 mg, GBP 1800 mg, GBP 2400 mg) than placebo, with significance indicated by p-values below 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

A formula illustrating creatinine clearance (CLCr) calculation, showing it as a function of age, weight, serum creatinine, and a factor for female patients. It is likely part of the pharmacokinetic or dosing information related to Gabapentin tablets, 600 mg, by Asclemed USA, Inc.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin, showing a cyclohexane ring connected to an aminomethyl group and an acetic acid group.*

FDA Label Image

Image-06 (Image 06)

A plot showing the difference percentage by daily dose (mg) of Gabapentin in three different studies labeled a, b, and c. The x-axis represents daily dose values (600, 900, 1200, 1800 mg), and the y-axis shows difference percentage up to 22%. Each study is represented by different markers with study a as black squares, study b as gray squares, and study c as white squares.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.